Novartis steps up coronavirus fight as part of new collaboration
Several big pharmaceutical companies have joined forces with the Bill & Melinda Gates Foundation to scale up solutions and support health systems in response to the coronavirus pandemic.
This content was published on
2 minutes
Keystone-SDA/jdp
العربية
ar
نوفارتيس تنشط كطرف في تحالف جديد لمكافحة الفيروس المستجد
On Thursday, Basel-based pharmaceutical giant Novartis announced that CEO Vas Narasimhan would be the co-chair of a consortium of life science companies to speed up the development and delivery of vaccines, diagnostics and treatments for Covid-19 as well as other solutions.
“We feel a deep shared responsibility to see if there are specific areas where collaboration across the life sciences industry and the Bill & Melinda Gates Foundation can accelerate solutions to this pandemic,” said Narasimhan in a statementExternal link.
More
More
Coronavirus: the situation in Switzerland
This content was published on
An overview of the latest Covid-related information in the Alpine nation.
The consortium is intended to help ramp up solutions and tap the industry’s scientific knowledge and experience in delivering products at a scale of billions per day.
As a first step, the 15 companies that are part of the consortium have agreed to share their proprietary libraries of molecular compounds with the Covid-19 Therapeutics Accelerator launched by the Gates Foundation, Wellcome, and Mastercard two weeks ago. The accelerator will screen them for potential use against Covid-19 and if there are successful hits, the compounds would move rapidly into in vivo trials in as little as two months.
Other companies that have teamed up in the consortium include GSK, Pfizer and Gilead. Gilead’s drug Remdesivir is an intravenous, antiviral medicine that is being studied in clinical trials as a treatment to Covid-19.
Last week, Novartis announced it was donating up to 130 million doses of generic hydroxychloroquine, which along with a related drug, chloroquine, is currently under evaluation in clinical trials for the treatment of Covid-19.
The company has also created a Covid-19 Response FundExternal link providing $20 million (CHF 19 million) in grants to support public health initiatives for communities affected by the pandemic.
Novartis is one of several big pharmaceutical companies that has moved out of the emerging infectious disease business. In 2014, the Swiss company sold its vaccine business to British pharma company GSK after operating at a loss for years. The company no longer has critical mass of expertise in virology, and no laboratories are working on antivirals or diagnostics.
External Content
Your subscription could not be saved. Please try again.
Almost finished… We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.
More
More
With no prospects for profits, big pharma neglects new infectious diseases
This content was published on
More companies are shifting resources away from emerging infectious diseases into more lucrative areas like cancer. What does this mean for Covid-19?
North African asylum claims fall after rapid Swiss processing
This content was published on
The accelerated procedure, now out of its test phase, has resulted in a significant drop in applications from North African countries.
This content was published on
The artist's song "The Code" focuses on their journey as a nonbinary individual. It is one of the favourites to win this year's contest.
Swiss climate activists block vehicles near Gotthard tunnel
This content was published on
Around ten climate activists briefly blocked the A2 motorway near the northern entrance of the Gotthard tunnel on Thursday.
Watches belonging to Michael Schumacher up for auction
This content was published on
Schumacher's family is auctioning off eight rare watches from his collection in Geneva. The Christie's auction will take place on Monday.
Joya Marleen and Baschi named best solo acts at Swiss Music Awards
This content was published on
St. Gallen singer Joya Marleen and Baschi from Basel were named artists of the year at the Swiss Music Awards 2024 on Wednesday night.
Swiss authorities announce cost-cutting in asylum sector
This content was published on
The government notably wants to improve integration into the labour force, particularly for people with protection status S.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Swiss pharma giants swallow up start-ups in push for next big gene therapy
This content was published on
Swiss drug makers are increasingly relying on buying science rather than doing it themselves in the search for the next big medical breakthrough.
Swiss restrict exports of protective equipment as coronavirus hits
This content was published on
Switzerland has introduced temporary restrictions on the export of protective equipment to head off shortages among medical staff and others.
This content was published on
US authorities have approved a $2.1 million gene therapy, making it the most expensive drug ever. Can such a price tag be justified?
This content was published on
As money is poured into the search for a silver bullet to Covid-19, some experts warn that the pandemic could also worsen the antibiotics crisis.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.